Literature DB >> 2999305

Neutralization of yellow fever virus studied using monoclonal and polyclonal antibodies.

A Buckley, E A Gould.   

Abstract

Monoclonal and polyclonal antibodies with known specificity for either the 54K envelope glycoprotein or the 48K non-structural glycoprotein of yellow fever (YF) virus-infected cells were studied in plaque reduction neutralization tests. Viruses employed in the tests comprised wild-type and vaccine strains of YF and a selection of other flaviviruses. Of 17 monoclonal antibodies examined, six of the 54K-specific antibodies neutralized at least one YF preparation. Both vaccine and wild-type YF viruses varied in their susceptibility to neutralization and there were also differences between individual 17D vaccine strains. The monoclonal antibodies produced a range of titres with the different viruses, the most potent, 864, leaving no non-neutralizable fraction. Addition of anti-globulin, complement or other antibodies did not affect the results. YF-neutralize antibodies which bound to other flaviviruses did not necessarily neutralize them; hence, neutralization could be defined as either homotypic, heterotypic or both homotypic and heterotypic. A polyclonal antiserum and a broadly reacting monoclonal antibody produced almost identical neutralization results in tests with wild-type YF viruses. In contrast, the polyclonal antiserum produced higher titres with vaccine strains of YF. In mouse passive protection experiments on the other hand, the monoclonal antibody did not differentiate between these viruses.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2999305     DOI: 10.1099/0022-1317-66-12-2523

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  10 in total

1.  Characterization of a siberian virus isolated from a patient with progressive chronic tick-borne encephalitis.

Authors:  T S Gritsun; T V Frolova; A I Zhankov; M Armesto; S L Turner; M P Frolova; V V Pogodina; V A Lashkevich; E A Gould
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Identification of amino acids recognized by syncytium-inhibiting and neutralizing monoclonal antibodies to the human parainfluenza type 3 virus fusion protein.

Authors:  K V Coelingh; E L Tierney
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

3.  Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function.

Authors:  J A Beeler; K van Wyke Coelingh
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

4.  Antigenic and functional organization of human parainfluenza virus type 3 fusion glycoprotein.

Authors:  K van Wyke Coelingh; E L Tierney
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

5.  Antigenic analysis of West Nile virus strains using monoclonal antibodies.

Authors:  T G Besselaar; N K Blackburn
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

6.  Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge.

Authors:  C Schmaljohn; L Vanderzanden; M Bray; D Custer; B Meyer; D Li; C Rossi; D Fuller; J Fuller; J Haynes; J Huggins
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

7.  A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease.

Authors:  Amanda E Calvert; Kandice L Dixon; Joseph Piper; Susan L Bennett; Brett A Thibodeaux; Alan D T Barrett; John T Roehrig; Carol D Blair
Journal:  Antiviral Res       Date:  2016-04-26       Impact factor: 5.970

8.  Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites.

Authors:  Karin Stiasny; Stefan Kiermayr; Heidemarie Holzmann; Franz X Heinz
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

9.  Thermodynamic mechanism for the evasion of antibody neutralization in flaviviruses.

Authors:  Rodrigo A Maillard; Tong Liu; David W C Beasley; Alan D T Barrett; Vincent J Hilser; J Ching Lee
Journal:  J Am Chem Soc       Date:  2014-07-08       Impact factor: 15.419

10.  Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody.

Authors:  T Trirawatanapong; B Chandran; R Putnak; R Padmanabhan
Journal:  Gene       Date:  1992-07-15       Impact factor: 3.688

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.